To the Editor: We read with great interest the European trial of cyclosporine alone versus antithymocyte globulin (ATG) and cyclosporin together for the treatment of patients with nonsevere aplastic anemia.[1][1] The results are very interesting and suggest that combined therapy is superior to
No takes yet. Share an insight, caveat, or question.
Reddy et al. (1999) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: